Immunohistochemistry Market Summary

The global immunohistochemistry (IHC) market size was valued at approximately USD 2.40 billion in 2024 and is anticipated to grow to around USD 3.50 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.93% during the forecast period from 2025 to 2030. This upward trajectory is largely attributed to the growing integration of automation technologies and machine learning applications in IHC processes. Furthermore, the consistent launch of technologically sophisticated IHC solutions is anticipated to be a primary factor propelling the market forward throughout the coming years.

Significant improvements in IHC protocols have notably increased their utilization in disease diagnosis. Alongside this, a surge in product approvals and the introduction of advanced immunohistochemistry systems have contributed to the expansion of the market. Supporting this development, many companies are continuously striving to introduce innovative platforms that match current technological standards while meeting the evolving demands of end-users. For instance, in December 2023, Biocare Medical introduced the intelliPATH+, a next-generation version of its successful intelliPATH FLX staining system. This updated system, designed using extensive user feedback and integrated with the latest innovations, offers an open system framework that delivers outstanding flexibility and efficiency for IHC workflows.

Key Market Trends & Insights

• In 2024, the antibodies segment accounted for the largest revenue share at 41.4%. This dominance is primarily due to the fundamental role antibodies play in disease diagnostics and drug testing. The market has seen an increased demand for monoclonal antibodies and related products such as Fc-fusion proteins, antibody fragments, and antibody-drug conjugates. These are widely adopted in fields like pathology, neuropathology, and hematopathology, positioning antibodies as a critical component in IHC-related applications.
• The diagnostics segment held the leading position in the market with a revenue share exceeding 68.6% in 2024 and is expected to maintain this dominance through the forecast period. IHC testing is a vital component in diagnosing numerous chronic conditions such as cancer, cardiovascular diseases, infectious diseases, autoimmune disorders, diabetes, and kidney-related ailments, thereby driving demand in this segment.
• Hospitals and diagnostic laboratories comprised the dominant end-use segment in 2024, contributing to over 70.4% of the total market revenue. This significant share is mainly due to the high volume of immunohistochemistry tests performed in hospital settings, where access to diagnostic infrastructure and skilled professionals is readily available.
• North America led the global immunohistochemistry market with a substantial revenue share of over 37.77% in 2024. This region's leadership position is attributed to the concentration of prominent industry players, ease of access to advanced IHC instruments, and rapid adoption of innovative diagnostic technologies. The United States, in particular, is witnessing notable growth due to its extensive research initiatives and substantial funding in cutting-edge diagnostic tools. Moreover, the growing emphasis on personalized medicine and the wide-scale use of IHC in oncology diagnostics are further fueling market growth in the country.
• The European immunohistochemistry market is demonstrating consistent progress, driven by robust academic research, well-established clinical infrastructure, and supportive regulatory policies that foster diagnostic advancements. Leading countries such as Germany, the United Kingdom, and France are increasingly integrating IHC in pathology laboratories, particularly for cancer diagnostics and biomarker identification.
• In the Asia Pacific region, the IHC market is expanding rapidly, influenced by a rise in chronic disease prevalence, improvements in diagnostic technology, and increasing research and development funding. Nations like China, Japan, and India are at the forefront of adopting IHC, especially in the field of cancer diagnostics. The increasing burden of cancer and the growing necessity for accurate and tailored diagnostic techniques are accelerating the region’s market growth.
• The immunohistochemistry market in the Middle East and Africa (MEA) is gradually gaining momentum, supported by growing investments in healthcare infrastructure and biotechnological research. Countries such as the UAE, Saudi Arabia, and South Africa are increasingly engaging in the development of IHC diagnostics and research initiatives, strengthening their foothold in the global market.

Order a free sample PDF of the Immunohistochemistry Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 2.40 billion
• 2030 Projected Market Size: USD 3.50 billion
• CAGR (2025-2030): 6.93%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Players

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global immunohistochemistry market is poised for steady expansion through 2030, driven by continuous advancements in diagnostic technology, automation, and personalized medicine. With significant contributions from antibodies, diagnostics, and hospital segments, the market reflects strong integration across healthcare ecosystems. Regional growth in North America, Europe, Asia Pacific, and the MEA underscores the widespread adoption of IHC in disease diagnosis, especially cancer. Rising research activities, innovative product launches, and supportive healthcare investments are setting the foundation for sustained development. As healthcare systems evolve, immunohistochemistry remains central to precise, efficient, and personalized diagnostic strategies worldwide.